Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq Stockholm
16:30:00 30/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 10.06 SEK | -2.71% |
|
+11.04% | +88.39% |
| 10-29 | Ten stocks have so far today hit new 52-week highs on the Stockholm Stock Exchange | FW |
| 10-28 | Six stocks have hit new 52-week highs on the Stockholm Stock Exchange so far today | FW |
| Market Cap | 4.68B 476M 426M 392M 355M 664M 45.21B 677M 1.88B 23.78B 1.79B 1.75B 74.99B | P/E 2026 * |
21.9x | P/E 2027 * | -46x |
|---|---|---|---|---|---|
| Enterprise Value | 3.68B 375M 336M 309M 280M 523M 35.59B 533M 1.48B 18.72B 1.41B 1.38B 59.04B | EV / Sales 2026 * |
6.85x | EV / Sales 2027 * | 7.65x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
CBOE
| Real-time | ||
|
London S.E.
| 0ABW | Delayed | |
|
OTC Markets
| PDPHF | Delayed | |
|
Boerse Muenchen
| P0F | Real-time | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -2.71% | ||
| 1 week | +11.04% | ||
| 1 month | +13.54% | ||
| 3 months | +67.67% | ||
| 6 months | +79.32% | ||
| Current year | +88.39% |
| 1 week | 9.08 |  | 10.82 |
| 1 month | 8.95 | | 10.82 |
| Current year | 4.23 | | 10.82 |
| 1 year | 3.62 | | 10.82 |
| 3 years | 3.02 | | 10.82 |
| 5 years | 3 | | 10.82 |
| 10 years | 3 | | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/09/26 | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 31/08/26 | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 31/08/26 | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.71% | +11.04% | +52.42% | +117.75% | 476M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.03% | +7.89% | +48.06% | +187.26% | 39.48B | |
| Weighted average by Cap. | +0.17% | +5.45% | +48.00% | +176.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 538M 54.73M 49.01M 45.08M 40.85M 76.36M 5.2B 77.79M 216M 2.73B 205M 201M 8.62B | 510M 51.96M 46.54M 42.81M 38.79M 72.5M 4.93B 73.86M 205M 2.6B 195M 191M 8.18B |
| Net income | 316M 32.16M 28.81M 26.5M 24.01M 44.88M 3.05B 45.72M 127M 1.61B 121M 118M 5.07B | -28.62M -2.91M -2.61M -2.4M -2.17M -4.06M -277M -4.14M -11.49M -146M -10.93M -10.7M -459M |
| Net Debt | -995M -101M -90.69M -83.42M -75.58M -141M -9.61B -144M -399M -5.06B -380M -372M -15.95B | -774M -78.74M -70.52M -64.87M -58.78M -110M -7.48B -112M -311M -3.93B -296M -289M -12.4B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | SEK 10.06 | -2.71% | 1,043,220 |
| 29/10/26 | SEK 10.34 | -.--% | 2,038,092 |
| 28/10/26 | SEK 10.34 | +5.83% | 3,624,112 |
| 27/10/26 | SEK 9.770 | +5.62% | 2,130,417 |
| 26/10/26 | SEK 9.250 | +2.10% | 1,235,137 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
